Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Path Holdings (NQ: BPTH )

2.196 +0.026 (+1.22%)
Streaming Delayed Price Updated: 11:48 AM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 37,353
Open 2.174
Bid (Size) 2.180 (12)
Ask (Size) 2.200 (5)
Prev. Close 2.170
Today's Range 2.170 - 2.200
52wk Range 1.273 - 4.478
Shares Outstanding 7,960,164
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q3 '22
Dallas, Texas--(Newsfile Corp. - December 19, 2022) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners updates coverage on Bio-Path... 
Via Newsfile
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
Phase 1/1b Clinical Trial Evaluating Ability of BP1001-A to Treat Patients with Solid Tumors, Including Ovarian, Endometrial, Pancreatic and Breast Cancer 
From Bio-Path Holdings, Inc.
Via Globe NewsWire

Performance

YTD
+46.43%
+46.43%
1 Month
+65.15%
+65.15%
3 Month
-33.64%
-33.64%
6 Month
-39.82%
-39.82%
1 Year
-35.77%
-35.77%

More News

Read More
Bio-Path Holdings Q3 2022 Earnings Conference Call On November 15, 2022 At 08:30 AM ET
Via Benzinga
Analyzing Bio-Path Holdings's Short Interest
Via Benzinga
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
From Bio-Path Holdings, Inc.
Via Globe NewsWire
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
From Bio-Path Holdings, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
From Bio-Path Holdings, Inc.
Via Globe NewsWire
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
From Bio-Path Holdings, Inc.
Via Globe NewsWire
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH)
Via Newsfile
Bio-Path Holdings: Q2 Earnings Insights
Via Benzinga
Earnings Scheduled For August 16, 2022
Via Benzinga
Earnings Outlook For Bio-Path Holdings
Via Benzinga
10 Biggest Price Target Changes For Thursday
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
Bio-Path Holdings: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For May 17, 2022
Via Benzinga
A Preview Of Bio-Path Holdings's Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Why Bio-Path Holdings Shares Are Rising After Hours
Via Benzinga
The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China
Via Benzinga
Bio-Path Holdings: Q4 Earnings Insights
Via Benzinga
Earnings Scheduled For March 11, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.